Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary

Journal of Pathology

Volumn 231, Issue 4, 2013, Pages 413-423

  Tothill, Richard W ^a,b   Li, Jason ^a   Mileshkin, Linda ^a,b   Doig, Ken ^a   Siganakis, Terence ^a   Cowin, Prue ^a   Fellowes, Andrew ^a   Semple, Timothy ^a   Fox, Stephen ^a   Byron, Keith ^c   Kowalczyk, Adam ^b   Thomas, David ^a   Schofield, Penelope ^a   Bowtell, David D ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Healthscope Pathology   (Australia)

Author keywords

cancer diagnostic; cancer of unknown primary; massively parallel sequencing; mutation profiling; next generation sequencing; targeted therapy

Indexed keywords

4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; AGI 5198; ANTINEOPLASTIC AGENT; CRIZOTINIB; DNA; FORMALDEHYDE; OLAPARIB; OLIGONUCLEOTIDE; PALBOCICLIB; PARAFFIN; PONATINIB; RUXOLITINIB; SC 66; SELUMETINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VISMODEGIB;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER OF UNKNOWN PRIMARY SITE; CONTROLLED STUDY; DNA DNA HYBRIDIZATION; DNA MICROARRAY; DRUG TARGETING; FEMALE; FLUORESCENCE ANALYSIS; GENE DOSAGE; GENE FREQUENCY; GENE INSERTION; GENE MUTATION; HUMAN; MALE; MASSIVELY PARALLEL SEQUENCING; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION;

CANCER DIAGNOSTIC; CANCER OF UNKNOWN PRIMARY; MASSIVELY-PARALLEL SEQUENCING; MUTATION PROFILING; NEXT-GENERATION SEQUENCING; TARGETED THERAPY;

ADULT; AGED; DNA COPY NUMBER VARIATIONS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; EVIDENCE-BASED MEDICINE; FEMALE; GENE EXPRESSION PROFILING; GENES, NEOPLASM; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS, UNKNOWN PRIMARY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 84887555902     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4251     Document Type: Article

References (64)

1. Pavlidis N, Pentheroudakis G,. Cancer of unknown primary site. Lancet 2012; 379: 1428-1435.
2. Pentheroudakis G, Golfinopoulos V, Pavlidis N,. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer 2007; 43: 2026-2036.
3. Tothill RW, Kowalczyk A, Rischin D, et al., An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res 2005; 65: 4031-4040.
4. Monzon FA, Lyons-Weiler M, Buturovic LJ, et al., Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. J Clin Oncol 2009; 27: 2503-2508.
5. Greco FA, Spigel DR, Yardley DA, et al., Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction. Oncologist 2010; 15: 500-506.
6. Horlings HM, van Laar RK, Kerst JM, et al., Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol 2008; 26: 4435-4441.
7. Varadhachary GR, Spector Y, Abbruzzese JL, et al., Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. Clin Cancer Res 2011; 17: 4063-4070.
8. Beck AH, Rodriguez-Paris J, Zehnder J, et al., Evaluation of a gene expression microarray-based assay to determine tissue type of origin on a diverse set of 49 malignancies. Am J Surg Pathol 2011; 35: 1030-1037.
9. Stratton MR, Campbell PJ, Futreal PA,. The cancer genome. Nature 2009; 458: 719-724.
10. Shepherd R, Forbes SA, Beare D, et al., Data mining using the Catalogue of Somatic Mutations in Cancer BioMart. Database (Oxford) 2011; 2011: bar018.
11. Massard C, Loriot Y, Fizazi K,. Carcinomas of an unknown primary origin-diagnosis and treatment. Nature Rev Clin Oncol 2011; 8: 701-710.
12. Fizazi K, Greco FA, Pavlidis N, et al., Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011; 22 (Suppl 6): vi64-68.
13. Li H, Durbin R,. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754-1760.
14. McKenna A, Hanna M, Banks E, et al., The Genome Analysis Toolkit a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 20: 1297-1303.
15. DePristo MA, Banks E, Poplin R, et al., A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nature Genet 2011; 43: 491-498.
16. Cibulskis K, Lawrence MS, Carter SL, et al., Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nature Biotechnol 2013; 31: 213-219.
17. Flicek P, Ahmed I, Amode MR, et al., Ensembl 2013. Nucleic Acids Res 2013; 41: D48-D55.
18. McLaren W, Pritchard B, Rios D, et al., Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics 2010; 26: 2069-2070.
19. Li J, Lupat R, Amarasinghe KC, et al., CONTRA: copy number analysis for targeted resequencing. Bioinformatics 2012; 28: 1307-1313.
20. Cowin PA, George J, Fereday S, et al., LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. Cancer Res 2012; 72: 4060-4073.
21. Gorringe KL, George J, Anglesio MS, et al., Copy number analysis identifies novel interactions between genomic loci in ovarian cancer. PLoS One 2010; 5: e11408.
22. Zhang L, Daly RJ,. Targeting the human kinome for cancer therapy: current perspectives. Crit Rev Oncog 2012; 17: 233-246.
23. Futreal PA, Coin L, Marshall M, et al., A census of human cancer genes. Nature Rev Cancer 2004; 4: 177-183.
24. Forbes SA, Tang G, Bindal N, et al., COSMIC (the Catalogue of Somatic Mutations in Cancer) a resource to investigate acquired mutations in human cancer. Nucleic Acids Res 2010; 38: D652-D657.
25. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337.
26. Rudd ML, Price JC, Fogoros S, et al., A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res 2011; 17: 1331-1340.
27. Schubbert S, Shannon K, Bollag G,. Hyperactive Ras in developmental disorders and cancer. Nature Rev Cancer 2007; 7: 295-308.
28. Carpten JD, Faber AL, Horn C, et al., A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007; 448: 439-444.
29. Forbes SA, Bindal N, Bamford S, et al., COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39: D945-D950.
30. Pleasance ED, Cheetham RK, Stephens PJ, et al., A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010; 463: 191-196.
31. Pleasance ED, Stephens PJ, O'Meara S, et al., A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010; 463: 184-190.
32. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature 2013; DOI: 10.1038/nature12477.
33. Borger DR, Tanabe KK, Fan KC, et al., Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 2012; 17: 72-79.
34. Paulson KG, Lemos BD, Feng B, et al., Array-CGH reveals recurrent genomic changes in Merkel cell carcinoma including amplification of L-Myc. J Invest Dermatol 2009; 129: 1547-1555.
35. Wagle N, Berger MF, Davis MJ, et al., High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2012; 2: 82-93.
36. Tran B, Brown AM, Bedard PL, et al., Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial. Int J Cancer 2013; 132: 1547-1555.
37. Lipson D, Capelletti M, Yelensky R, et al., Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nature Med 2012; 18: 382-384.
38. Hale KS, Wang H, Karanth S, et al., Mutation profiling in patients with carcinoma of unknown primary using the Sequenom MassARRAY system. J Clin Oncol 2012; 30 (Suppl): Abstr 4131.
39. Ohta S, Cho Y, Shibata M, et al., Possibility of molecular targeting therapy for the treatment of cancer of unknown primary origin by analysis of intracellular signaling molecules. Exp Ther Med 2012; 3: 547-549.
40. Alexandrov LB, Nik-Zainal S, Wedge DC, et al., Deciphering signatures of mutational processes operative in human cancer. Cell Rep 2013; 3: 246-259.
41. Lawrence MS, Stojanov P, Polak P, et al., Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499: 214-218.
42. Stella GM, Benvenuti S, Gramaglia D, et al., MET mutations in cancers of unknown primary origin (CUPs). Hum Mutat 2010; 32: 44-50.
43. Jo H, Lo PK, Li Y, et al., Deactivation of Akt by a small molecule inhibitor targeting pleckstrin homology domain and facilitating Akt ubiquitination. Proc Natl Acad Sci U S A 2011; 108: 6486-6491.
44. Janku F, Wheler JJ, Westin SN, et al., PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 2012; 30: 777-782.
45. Janne PA, Shaw AT, Pereira JR, et al., Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013; 14: 38-47.
46. Farley J, Brady WE, Vathipadiekal V, et al., Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol 2013; 14: 134-140.
47. Allegra CJ, Jessup JM, Somerfield MR, et al., American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27: 2091-2096.
48. Saini KS, Loi S, de Azambuja E, et al., Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat Rev 2013; 39: 935-946
49. Rodig SJ, Shapiro GI,. Crizotinib a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr Opin Invest Drugs 2010; 11: 1477-1490.
50. Guagnano V, Kauffmann A, Wohrle S, et al., FGFR genetic alterations predict for sensitivity to NVP-BGJ398 a selective pan-FGFR inhibitor. Cancer Discov 2012; 2: 1118-1133.
51. Chase A, Bryant C, Score J, et al., Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements. Haematologica 2013; 98: 404-408.
52. Gozgit JM, Wong MJ, Moran L, et al., Ponatinib (AP24534) a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther 2012; 11: 690-699.
53. Finn R,. Results of a randomized phase 2 study of PD 0332991 a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (BC). Cancer Res 2012; 72 (Suppl 24): S1-6.
54. Fong PC, Boss DS, Yap TA, et al., Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134.
55. Kaufman B, Shapira-Frommer R, Schmutzler RK, et al., Olaparib monotherapy in patients with advanced cancer and a germ-line BRCA1/2 mutation: an open-label phase II study. J Clin Oncol 2013; 31 (Suppl): Abstr 11024.
56. Sekulic A, Migden MR, Oro AE, et al., Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012; 366: 2171-2179.
57. Dang L, White DW, Gross S, et al., Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2010; 465: 966.
58. Rohle D, Popovici-Muller J, Palaskas N, et al., An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013; 340: 626-630.
59. Figueroa ME, Abdel-Wahab O, Lu C, et al., Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18: 553-567.
60. Prahallad A, Sun C, Huang S, et al., Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483: 100-103.
61. Sleijfer S, Bogaerts J, Siu LL,. Designing transformative clinical trials in the cancer genome era. J Clin Oncol 2013; 31: 1834-1841.
62. Lillie EO, Patay B, Diamant J, et al., The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Per Med 2011; 8: 161-173.
63. Pavlidis N., Cancer of unknown primary: biological and clinical characteristics. Ann Oncol 2003; 14 (Suppl 3): iii11-18.
64. Vogelstein B, Papadopoulos N, Velculescu VE, et al., Cancer genome landscapes. Science 2013; 339: 1546-1558.